{"id":4401,"date":"2025-03-31T18:12:07","date_gmt":"2025-03-31T18:12:07","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/tenecteplase-txt\/"},"modified":"2025-03-31T18:12:07","modified_gmt":"2025-03-31T18:12:07","slug":"tenecteplase-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/tenecteplase-txt\/","title":{"rendered":"Tenecteplase.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nThrombolytic:Acute myocardial infarction

DOSE IN NORMAL RENAL FUNCTION <\/H3>30\u201350 mg depending on patient weight (500\u2013600 micrograms\/kg)

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :70 000<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : Minimal<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :6.1\u20139.1 litres1 (weight and dose related)<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :90\u2013130 minutes\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsDrugs that affect coagulation or platelet function: increased risk of bleeding

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>Water for injection

    Route <\/H4>IV

    Rate of Administration <\/H4>Over 10 seconds

    Comments<\/H4>Incompatible with dextrose

    OTHER INFORMATION <\/H4>It has an initial half-life of 20\u201324 minutes Cleared mainly by hepatic metabolism Re-administration is not recommended due to lack of experience
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Thrombolytic:Acute myocardial infarction DOSE IN NORMAL RENAL FUNCTION<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4401","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4401"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4401\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}